CLAIMS

What is claimed is:

1. Compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof for use in combination with a cholinesterase inhibitor for the treatment of Alzheimer's disease in a patient.

2. Compound for use according to claim 1, as an adjunct treatment in a patient on stable treatment with a cholinesterase inhibitor

3. Compound for use according to claim 1 or 2, in which the patient has dementia of the Alzheimer's type (DAT).

4. Compound for use according to claim 1 or 2, in which the patient has mild Alzheimer's disease.

5. Compound for use according claim 1 or 2, in which the patient has moderate Alzheimer's disease.

6. Compound for use according to any one of claims 1 to 5, in which the progression of the symptoms of dementia are suppressed.

7. Compound for use according to any one of claims 1 to 6, in which about 5 mg per day of 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or pharmaceutically acceptable salt thereof is administered to the patient.

8. Compound for use according to any one of claims 1 to 7, in which the 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or pharmaceutically acceptable salt thereof is administered to the patient simultaneously with the cholinesterase inhibitor.

9. Compound for use according to any one of claims 1 to 8, in which the 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or pharmaceutically acceptable salt thereof and cholinesterase inhibitor are each administered to the patient in a therapeutically effective amount with respect to the individual components.

10. Compound for use according to any one of claims 1 to 9, in which the 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or pharmaceutically acceptable salt thereof is 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate.

11. Compound for use according to any one of claims 1 to 10, in which the cholinesterase inhibitor is selected from the group consisting of galantamine, rivastigmine, donepezil, mimopezil, ladostigil, and huperzine A; or a pharmaceutically acceptable salt thereof.

12. Compound for use according to any one of claims 1 to 10, in which the cholinesterase inhibitor is selected from the group consisting of galantamine, rivastigmine, and donepezil; or a pharmaceutically acceptable salt thereof.

13. Compound for use according to any one of claims 1 to 10, in which the cholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

14. Compound for use according to claim 13, in which the donepezil or a pharmaceutically acceptable salt thereof is donepezil hydrochloride.

15. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises a reduction in the worsening of cognitive function of the patient.

16. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises a reduction in the worsening of functional capability of the patient.

17. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises a reduction in the worsening of attention of the patient.

18. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises a maintenance or reduction in the symptoms of apathy of the patient.

19. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises an increase in patient responder rate based on a combined criterion, measured with ADAS-Cog and ADCS-ADL and CGIC.

20. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises a maintenance in a sleep parameter selected from the group consisting of total sleep time, number of awakenings, interdaily variability and intradaily stability.

21. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises an alteration in a sleep parameter selected from the group consisting of sleep fragmentation, sleep efficiency, wake after sleep onset, mean awakening duration and relative amplitude.

22. Compound for use according to any one of claims 1 to 14, wherein the treatment comprises an improvement in episodic memory of the patient.